{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:38:09Z","timestamp":1790685489789,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.bcp.2006.05.007","type":"journal-article","created":{"date-parts":[[2006,5,14]],"date-time":"2006-05-14T11:11:36Z","timestamp":1147605096000},"page":"427-436","source":"Crossref","is-referenced-by-count":40,"title":["Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells"],"prefix":"10.1016","volume":"72","author":[{"given":"Shlomit","family":"Erlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pazit","family":"Tal-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Liebling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devarajan","family":"Karunagaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoel","family":"Kloog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Pinkas-Kramarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2006.05.007_bib1","doi-asserted-by":"crossref","first-page":"D372","DOI":"10.2741\/Amanatullah","article-title":"Cell-cycle dysregulation and the molecular mechanisms of prostate cancer","volume":"5","author":"Amanatullah","year":"2000","journal-title":"Front Biosci"},{"key":"10.1016\/j.bcp.2006.05.007_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s003450000186","article-title":"Systemic treatment of hormone refractory prostate cancer","volume":"19","author":"Rubben","year":"2001","journal-title":"World J Urol"},{"key":"10.1016\/j.bcp.2006.05.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-004-0473-1","article-title":"Mechanisms of the development of androgen independence in prostate cancer","volume":"23","author":"So","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.bcp.2006.05.007_bib4","first-page":"181","article-title":"Epidermal growth factor receptor and other oncogenes as prognostic markers","volume":"11","author":"Harris","year":"1992","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.bcp.2006.05.007_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C","article-title":"Regulation of prostatic growth and function by peptide growth factors","volume":"28","author":"Culig","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.bcp.2006.05.007_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s002400000111","article-title":"Androgen receptor \u2013 an update of mechanisms of action in prostate cancer","volume":"28","author":"Culig","year":"2000","journal-title":"Urol Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib7","first-page":"545","article-title":"Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms","volume":"1","author":"Scher","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib8","first-page":"3438","article-title":"Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer","volume":"8","author":"Di Lorenzo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1073\/pnas.91.3.1064","article-title":"Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development","volume":"91","author":"Meyer","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.bcp.2006.05.007_bib10","first-page":"3174","article-title":"Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene","volume":"52","author":"Sikes","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib11","first-page":"367","article-title":"Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis","volume":"14","author":"Schwartz","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bcp.2006.05.007_bib12","first-page":"2789","article-title":"Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations","volume":"18","author":"Shiraishi","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib13","first-page":"6830","article-title":"Ras gene mutations in human prostate cancer","volume":"50","author":"Carter","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib14","first-page":"5991","article-title":"Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas","volume":"52","author":"Anwar","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib15","first-page":"279","article-title":"Activation of mitogen-activated protein kinase associated with prostate cancer progression","volume":"59","author":"Gioeli","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib16","first-page":"1981","article-title":"Constitutive activation of the Ras\/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells","volume":"63","author":"Bakin","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.pcan.4500491","article-title":"Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer","volume":"4","author":"Sepp-Lorenzino","year":"2001","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.bcp.2006.05.007_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/erc.0.0110051","article-title":"Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments","volume":"11","author":"Melisi","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bcp.2006.05.007_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pros.20122","article-title":"Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival","volume":"62","author":"Shi","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.bcp.2006.05.007_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0925-4439(97)00077-X","article-title":"Stringent structural requirements for anti-Ras activity of S-prenyl analogues","volume":"1406","author":"Aharonson","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2006.05.007_bib21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/bi972032d","article-title":"Dislodgment and accelerated degradation of Ras","volume":"37","author":"Haklai","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2006.05.007_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid","volume":"1452","author":"Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2006.05.007_bib23","doi-asserted-by":"crossref","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","article-title":"Selective inhibition of Ras-dependent cell growth by farnesylthiosalicylic acid","volume":"270","author":"Marom","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2006.05.007_bib24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pros.10336","article-title":"The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro","volume":"58","author":"McPherson","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.bcp.2006.05.007_bib25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jm00008a004","article-title":"Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth","volume":"38","author":"Marciano","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2006.05.007_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"Mosman","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bcp.2006.05.007_bib27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1006\/bbrc.1997.7582","article-title":"The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation","volume":"239","author":"Gana-Weisz","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2006.05.007_bib28","first-page":"2720","article-title":"Frequent inactivation of PTEN in prostate cancer cell lines and xenografts","volume":"58","author":"Vlietstra","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/387422a0","article-title":"Myc and Ras collaborate in inducing accumulation of active cyclin E\/Cdk2 and E2F","volume":"387","author":"Leone","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2006.05.007_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/386177a0","article-title":"Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein","volume":"386","author":"Peeper","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2006.05.007_bib31","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1074\/jbc.R100063200","article-title":"Signaling networks that link cell proliferation and cell fate","volume":"277","author":"Sears","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2006.05.007_bib32","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1128\/MCB.15.7.3654","article-title":"Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells","volume":"15","author":"Liu","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bcp.2006.05.007_bib33","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1101\/gad.12.16.2469","article-title":"Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo","volume":"12","author":"Robles","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.bcp.2006.05.007_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/hmg\/10.7.699","article-title":"The Rb\/E2F pathway and cancer","volume":"10","author":"Nevins","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bcp.2006.05.007_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.cdd.4401334","article-title":"Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor","volume":"11","author":"Shalom-Feuerstein","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bcp.2006.05.007_bib36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.cdd.4400713","article-title":"M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK\/ERK-independent pathways","volume":"7","author":"Leloup","year":"2000","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bcp.2006.05.007_bib37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(05)70294-4","article-title":"Anti-apoptosis gene, survivin, and prognosis of neuroblastoma","volume":"351","author":"Adida","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2006.05.007_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3835(00)00677-7","article-title":"Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients","volume":"163","author":"Okada","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bcp.2006.05.007_bib39","first-page":"15","article-title":"IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"Tamm","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib40","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1038\/sj.onc.1206509","article-title":"Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras","volume":"22","author":"Sommer","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2006.05.007_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0960-0760(95)00086-F","article-title":"Growth of the androgen-dependent tumor of the prostate: role of androgens and of locally expressed growth modulatory factors","volume":"53","author":"Limonta","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bcp.2006.05.007_bib42","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0022-5347(17)32335-2","article-title":"Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues","volume":"152","author":"Cohen","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.bcp.2006.05.007_bib43","doi-asserted-by":"crossref","first-page":"14019","DOI":"10.1073\/pnas.96.24.14019","article-title":"Novel Ras antagonist blocks human melanoma growth","volume":"96","author":"Jansen","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2006.05.007_bib44","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1158\/1078-0432.CCR-04-2071","article-title":"Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest","volume":"11","author":"Yaari","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.999.65.3","article-title":"Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death","volume":"65","author":"Blum","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib46","first-page":"555","article-title":"The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance","volume":"8","author":"Gana-Weisz","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2006.05.007_bib47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/cbt.3.2.751","article-title":"Survivin\u2019 cancer","volume":"3","author":"Emens","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bcp.2006.05.007_bib48","first-page":"3937","article-title":"Functional evaluation of p53 and PTEN gene mutations in gliomas","volume":"6","author":"Kato","year":"2000","journal-title":"Clin Cancer Res"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295206002905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295206002905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T12:23:53Z","timestamp":1683462233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295206002905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0006295206002905"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2006.05.007","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}